DETAILED ACTION
Election/Restrictions
Applicant’s election without traverse of species SEQ ID NOs: 25 and 19, GLP1 SEQ ID NO: 232 and FGF21 SEQ ID NO: 234 in the reply filed on 7/16/2026 are acknowledged. After further consideration the species election is hereby withdrawn, and all species will be examined.
Claims 102-121 are pending and will be examined on the merits.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 102, 105-107, 109-113 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Boettcher et al. (WO/2013/049234, published 4/4/2013).
The Claims are drawn to an immunoglobulin fusion protein comprising an antibody variable domain region, a first extender fusion region comprising a GLP1 peptide and a second extender fusion region comprising an FGF21 peptide and a linker peptide.
Boettcher et al. teach a dual function fusion protein comprising a GLP-1 receptor agonist region and an FGF21 receptor agonist region (see claim 1). Boettcher et al. further disclose “the GLP-1 receptor agonist is fused to the N-terminus of heavy and light chain of an antibody and FGF21 is simultaneously fused to the C-terminus of heavy and light chain of the same antibody (i.e., a fusobody, as described herein)” (see paragraph [00023]). Boettcher et al. teach GLP-1 and FGF21 sequences having 90% identity to instantly claimed SEQ ID NOs: 228, 232, and 234 as well as linkers having instantly claimed SEQ ID NOs: 179 and 180 (see table 1 and paragraph [000286]).
Conclusion
Claims 102, 105-107, 109-113 are rejected.
Claims 103, 104, 108, 114-117 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claims 118-121 are allowable.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEERA NATARAJAN whose telephone number is (571)270-3058. The examiner can normally be reached M-F 9AM - 5PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JULIE WU can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Meera Natarajan/Primary Examiner, Art Unit 1643
Prosecution Insights